Show simple item record

dc.contributor.authorVaccaro, Christine M
dc.contributor.authorMutema, George K
dc.contributor.authorFellner, Angela N
dc.contributor.authorCrisp, Catrina C
dc.contributor.authorEstanol, Maria V
dc.contributor.authorKleeman, Steven D
dc.contributor.authorPauls, Rachel N
dc.date.accessioned2018-09-12T06:29:58Z
dc.date.accessioned2020-02-07T10:17:05Z
dc.date.available2018-09-12T06:29:58Z
dc.date.available2020-02-07T10:17:05Z
dc.date.issued2013
dc.identifier.urihttp://repository.must.ac.ke/handle/123456789/1378
dc.description.abstractThis study aimed to evaluate the histologic and cytologic effects of preoperative vaginal estrogen in women with atrophic vaginitis and pelvic organ prolapse.Forty-two women with atrophic vaginitis and stage greater than or equal to 2 prolapse were enrolled in this assessor-blinded randomized controlled trial comparing daily vaginal estrogen cream use for 2 to 12 weeks preoperatively versus no intervention. Data were analyzed using t test and analysis of variance.Of these 42 women, 22 received treatment and 20 were controls. After a mean 7 (3) weeks of use, the vaginal maturity index increased 15.5% in the treatment group and declined 1.5% in the control group (P < 0.001). The vaginal epithelial thickness was 339 (96) μm in the treatment group compared to 302 (119) μm (P = 0.275) in the controls.Preoperative vaginal estrogen application for 2 to 12 weeks restores vaginal cytology to premenopausal levels, but does not increase vaginal epithelial thickness in women with prolapse.en_US
dc.language.isoenen_US
dc.publisherLWWen_US
dc.titleHistologic and cytologic effects of vaginal estrogen in women with pelvic organ prolapse: a randomized controlled trialen_US
dc.typeArticleen_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record